UNSPSC 51422112: Clocortolone pivalate

This classification denotes a therapeutic glucocorticoid with the molecular formula C27H36ClFO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QBL8IZH14X, chemically known as 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-pivalate but more generally known as clocortolone pivalate, which bears US NIH Compound Identifier 36673. European Medicines Agency schedules Clocortolone pivalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13393MIG.

UNSPSC 51422112 Clocortolone pivalate is a Commodity code for a specific topical corticosteroid pharmaceutical product; however, the recent state and local procurement activity tagged under this code does not align with clocortolone pivalate itself. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking to procure naloxone and safe drug deactivation systems—opioid-overdose reversal medication and related harm-reduction equipment—rather than the corticosteroid the code nominally describes. The mismatch suggests either a coding error in the county's tagging or a broader classification practice at the issuing jurisdiction that does not map precisely to UNSPSC commodity boundaries. State and local governments soliciting under this code are primarily county public health departments and community health agencies focused on emergency response and substance-use initiatives, though the narrow recent activity limits firm conclusions about issuing-body distribution.

Seminole County's procurement represents the primary visible recent activity under this code, with a response deadline of July 26, 2023 (now closed) and a contract structure providing for quarterly deliveries and an initial two-year term with optional one-year renewal. The solicitation required bids on a fixed-fee basis through the county's e-Procurement Portal, with bidders expected to cover all shipping and delivery costs and comply with drug-free workplace certification, E-Verify, and federal environmental regulations tied to potential FEMA funding. No explicit set-asides for disadvantaged enterprises were named. Beyond this single opportunity in Florida, the source provides no additional recent state and local procurements under this code, limiting visibility into whether the code sees activity in other jurisdictions or geographic regions. Business development professionals should verify whether their firm's pharmaceutical or medical-device capabilities align with harm-reduction products rather than dermatological therapeutics before pursuing similar state and local opportunities under this classification.